Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Expands By 73.4%

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 2,410,000 shares, a growth of 73.4% from the October 15th total of 1,390,000 shares. Based on an average daily trading volume, of 525,700 shares, the short-interest ratio is currently 4.6 days.

Hedge Funds Weigh In On Aclaris Therapeutics

Hedge funds have recently bought and sold shares of the company. BML Capital Management LLC boosted its holdings in Aclaris Therapeutics by 9.7% in the third quarter. BML Capital Management LLC now owns 14,250,000 shares of the biotechnology company’s stock valued at $16,388,000 after purchasing an additional 1,261,866 shares during the period. Vanguard Group Inc. raised its holdings in Aclaris Therapeutics by 4.4% in the first quarter. Vanguard Group Inc. now owns 4,929,775 shares of the biotechnology company’s stock valued at $6,113,000 after acquiring an additional 207,418 shares in the last quarter. Millennium Management LLC lifted its stake in Aclaris Therapeutics by 1.9% in the second quarter. Millennium Management LLC now owns 3,336,850 shares of the biotechnology company’s stock worth $3,671,000 after acquiring an additional 63,358 shares during the last quarter. Stonepine Capital Management LLC purchased a new stake in shares of Aclaris Therapeutics in the 2nd quarter valued at approximately $2,120,000. Finally, Trium Capital LLP raised its holdings in shares of Aclaris Therapeutics by 1.1% in the 3rd quarter. Trium Capital LLP now owns 1,912,990 shares of the biotechnology company’s stock valued at $2,200,000 after purchasing an additional 20,940 shares in the last quarter. Institutional investors and hedge funds own 98.34% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ACRS shares. StockNews.com cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 7th. HC Wainwright reiterated a “neutral” rating on shares of Aclaris Therapeutics in a research note on Tuesday, September 17th.

Aclaris Therapeutics Stock Down 4.7 %

Shares of ACRS opened at $2.44 on Thursday. Aclaris Therapeutics has a 52-week low of $0.63 and a 52-week high of $2.72. The stock has a fifty day simple moving average of $1.43 and a two-hundred day simple moving average of $1.28.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.03). The firm had revenue of $4.35 million during the quarter, compared to analyst estimates of $8.31 million. Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. As a group, research analysts predict that Aclaris Therapeutics will post -0.65 EPS for the current fiscal year.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.